Novavax (NVAX) Receivables - Other (2016 - 2025)
Historic Receivables - Other for Novavax (NVAX) over the last 12 years, with Q3 2025 value amounting to $5.2 million.
- Novavax's Receivables - Other fell 1612.9% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 1612.9%. This contributed to the annual value of $5.4 million for FY2024, which is 5000.0% down from last year.
- Per Novavax's latest filing, its Receivables - Other stood at $5.2 million for Q3 2025, which was down 1612.9% from $5.3 million recorded in Q2 2025.
- Over the past 5 years, Novavax's Receivables - Other peaked at $68.0 million during Q3 2022, and registered a low of $200000.0 during Q1 2024.
- Moreover, its 5-year median value for Receivables - Other was $28.6 million (2022), whereas its average is $26.9 million.
- Per our database at Business Quant, Novavax's Receivables - Other tumbled by 9953.16% in 2024 and then soared by 295000.0% in 2025.
- Novavax's Receivables - Other (Quarter) stood at $35.3 million in 2021, then decreased by 18.98% to $28.6 million in 2022, then crashed by 62.24% to $10.8 million in 2023, then tumbled by 50.0% to $5.4 million in 2024, then fell by 3.7% to $5.2 million in 2025.
- Its last three reported values are $5.2 million in Q3 2025, $5.3 million for Q2 2025, and $6.1 million during Q1 2025.